1-bromo-5-ethyl-2,4-dimethoxybenzene | 19345-66-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 1-bromo-5-ethyl-2,4-dimethoxybenzene
• 英文别名: 4-Ethyl-6-bromoresorcinol-dimethylether；1-ethyl-5-bromo-2,4-dimethoxy-benzene；1-Aethyl-5-brom-2,4-dimethoxy-benzol
• CAS: 19345-66-5
• 化学式: C₁₀H₁₃BrO₂
• 分子量: 245.116
• InChiKey: KRVGAQWXFXTZLG-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  3.6
• 重原子数：
  13
• 可旋转键数：
  3
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.4
• 拓扑面积：
  18.5
• 氢给体数：
  0
• 氢受体数：
  2

反应信息

• 作为反应物：
  描述：

  1-bromo-5-ethyl-2,4-dimethoxybenzene 在 吗啉 、 bis-triphenylphosphine-palladium(II) chloride 、 copper(l) iodide 、 正丁基锂 、 1,1'-双(二苯膦基)二茂铁二氯化钯(II)二氯甲烷复合物 、 碘 、 caesium carbonate 、 三乙胺 、 sodium hydroxide 作用下， 以 四氢呋喃 、 甲醇 、 乙醚 、 氯仿 、 水 、 N,N-二甲基甲酰胺 、 甲苯 为溶剂， 反应 71.25h， 生成 methyl 2-(4-(5-ethyl-2,4-dihydroxyphenyl)-5-(3-(methylsulfonamido)phenyl)-1H-triazol-1-yl)acetate
  参考文献：
  名称：

  Discovery of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl)acetates as potent Hsp90 inhibitors with selectivity over TRAP1

  摘要：

  As the most abundant heat shock protein (HSP), Hsp90 is actively involved in tumor cell growth and various responses to anti-carcinogenic stress. Hsp90 has thus emerged as a potential drug target. A structure-based drug design approach was applied to develop novel resorcinolyltriazole derivatives as Hsp90 inhibitors. Structure-activity relationships (SARs) and molecular docking were investigated to provide a rationale for binding affinity and paralog selectivity. Click chemistry between iodoethynylresorcinol and an azido derivative was used to synthesize a new family of 2-((4-resorcinolyl)-5-aryl-1,2,3-triazol-1-yl) acetates that exhibited Hsp90 binding affinities of 40-100 nM (IC50). Among the synthesized molecules, the triazole alkyl acetates displayed the highest Hsp90 binding affinities. Their potency against Hsp90 was over 100-fold stronger than against TRAP1 and 1-3-fold stronger than against Grp94. In particular, compounds 18, 19, and 30 had Hsp90 inhibitory activities of similar to 45 nM (IC50) and they displayed over 350-fold selectivity for Hsp90 over TRAP1.

  DOI：

  10.1016/j.bmcl.2019.126809
• 作为产物：
  描述：

  1-(5-溴-2,4-二甲氧基苯基)乙-1-酮 在 盐酸 、 amalgamated zinc 、 苯 作用下， 生成 1-bromo-5-ethyl-2,4-dimethoxybenzene
  参考文献：
  名称：

  Feng; Chiu, Huaxue Xuebao/Acta Chimica Sinica, 1959, vol. 25, p. 277,285

  摘要：

  DOI：

文献信息

• [EN] INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME<br/>[FR] INHIBITEURS DE POLYMERASE D'ARN DEPENDANT D'ARN DU VIRUS DE L'HEPATITE C ET COMPOSITIONS ET TRAITEMENT UTILISANT CES INHIBITEURS
  申请人：PFIZER

  公开号：WO2006018725A1

  公开（公告）日：2006-02-23

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了公式（4）的化合物，以及它们的药学上可接受的盐和溶剂化合物，这些化合物可用作肝炎病毒（HCV）聚合酶酶的抑制剂，并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含公式（4）的化合物、其药学上可接受的盐和溶剂的药物组合物。此外，本发明提供了制备公式（4）化合物的中间体化合物和方法。
• Inhibitors of hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Gonzalez Javier

  公开号：US20060122399A1

  公开（公告）日：2006-06-08

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了式（4）的化合物及其药学上可接受的盐和溶剂，它们可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且对于治疗HCV感染的HCV感染的哺乳动物也有用。本发明还提供了包含式（4）的化合物、其药学上可接受的盐和溶剂的药物组合物。此外，本发明还提供了中间体化合物和用于制备式（4）化合物的有用方法。
• Inhibitors of Hepatitis C virus RNA-dependent RNA polymerase, and compositions and treatments using the same
  申请人：Agouron Pharmaceuticals, Inc.

  公开号：US07151105B2

  公开（公告）日：2006-12-19

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了公式（4）的化合物及其药学上可接受的盐和溶剂，它们可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且对于治疗HCV感染的HCV感染哺乳动物也很有用。本发明还提供了包括公式（4）的化合物、其药学上可接受的盐和溶剂的制药组合物。此外，本发明还提供了制备公式（4）化合物的中间体化合物和有用方法。
• INHIBITORS OF HEPATITIS C VIRUS RNA-DEPENDENT RNA POLYMERASE, AND COMPOSITIONS AND TREATMENTS USING THE SAME
  申请人：Gonzalez Javier

  公开号：US20070015764A1

  公开（公告）日：2007-01-18

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了公式(4)的化合物及其药学上可接受的盐和溶剂，这些化合物可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且还可用于治疗HCV感染的HCV感染哺乳动物。本发明还提供了包含公式(4)的化合物、其药学上可接受的盐和溶剂的制药组合物。此外，本发明还提供了中间体化合物和制备公式(4)的方法。
• Inhibitors of Hepatitis C Virus RNA-Dependent RNA Polymerase, and Compositions and Treatments Using the Same
  申请人：Gonzalez Javier

  公开号：US20090281122A1

  公开（公告）日：2009-11-12

  The present invention provides compounds of formula (4), and their pharmaceutically acceptable salts and solvates, which are useful as inhibitors of the Hepatitis C virus (HCV) polymerase enzyme and are also useful for the treatment of HCV infections in HCV-infected mammals. The present invention also provides pharmaceutical compositions comprising compounds of formula (4), their pharmaceutically acceptable salts and solvates. Furthermore, the present invention provides intermediate compounds and methods useful in the preparation of compounds of formula (4).

  本发明提供了式（4）的化合物及其药学上可接受的盐和溶剂化物，它们可用作丙型肝炎病毒（HCV）聚合酶酶的抑制剂，并且也可用于治疗HCV感染的HCV感染的哺乳动物。本发明还提供了包含式（4）的化合物、它们的药学上可接受的盐和溶剂化物的制药组合物。此外，本发明还提供了用于制备式（4）的化合物的中间体和方法。